You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Carfilzomib

Showing 1 - 25 of 227
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial (Carfilzomib, Cyclophosphamide, Dexamethasone)

Not yet recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • Carfilzomib
  • +2 more
  • (no location specified)
Jun 8, 2023

Multiple Myeloma Trial in Detroit, Charlotte (Carfilzomib, Ruxolitinib, Dexamethasone)

Active, not recruiting
  • Multiple Myeloma
  • Carfilzomib
  • +2 more
  • Detroit, Michigan
  • +1 more
Jan 27, 2023

Multiple Myeloma Trial in West Hollywood, Cary (Selinexor, Placebo (for selinexor), carfilzomib)

Withdrawn
  • Multiple Myeloma
  • West Hollywood, California
  • +1 more
Jan 24, 2023

Refractory Multiple Myeloma, Relapsed Multiple Myeloma Trial in Miami (Iberdomide, Carfilzomib, Daratumumab)

Not yet recruiting
  • Refractory Multiple Myeloma
  • Relapsed Multiple Myeloma
  • Miami, Florida
    University of Miami
May 31, 2023

Multiple Myeloma Trial in Seoul (Carfilzomib 56 MG [Kyprolis], Pomalidomide, Dexamethasone)

Recruiting
  • Multiple Myeloma
  • Carfilzomib 56 MG [Kyprolis]
  • +2 more
  • Seoul, Korea, Republic of
    Samsung Medical Center
Aug 19, 2022

Multiple Myeloma, Primary Plasma Cell Leukemia, Extramedullary Multiple Myeloma Trial in Wuhan (Daratumumab, Carfilzomib,

Recruiting
  • Multiple Myeloma
  • +2 more
  • Wuhan, Hubei, China
    Institute of Hematology, Union Hospital, Tongji Medical College,
Nov 18, 2023

Multiple Myeloma, Relapse Multiple Myeloma Trial in Chicago (Belantamab mafodotin, Carfilzomib, Pomalidomide)

Not yet recruiting
  • Multiple Myeloma
  • Relapse Multiple Myeloma
  • Belantamab mafodotin
  • +3 more
  • Chicago, Illinois
    University of Chicago Medicine Comprehensive Cancer Center
Mar 23, 2023

Relapsed/Refractory Multiple Myeloma Trial (Isatuximab, Carfilzomib, Dexamethasone)

Not yet recruiting
  • Relapsed/Refractory Multiple Myeloma
  • (no location specified)
Feb 3, 2023

Multiple Myeloma Trial in Beverly Hills (Elranatamab, Carfilzomib)

Recruiting
  • Multiple Myeloma
  • Beverly Hills, California
    Beverly Hills Cancer Center
Dec 21, 2022

Multiple Myeloma Trial run by the National Cancer Institute (NCI) (Dexamethasone, Carfilzomib, Daratumumab)

Recruiting
  • Multiple Myeloma
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 23, 2023

Multiple Myeloma Trial in United States (Isatuximab, Carfilzomib, Dexamethasone)

Recruiting
  • Multiple Myeloma
  • Isatuximab
  • +2 more
  • San Francisco, California
  • +3 more
Dec 24, 2022

Carfilzomib in Patients With Multiple Myeloma

Recruiting
  • Multiple Myeloma
  • Carfilzomib
  • Odense, Denmark
    Odense University Hospital
Dec 20, 2022

Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in Poitiers (Isatuximab, Carfilzomib, Pomalidomide)

Active, not recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • Poitiers, France
    CHU Poitiers
Jan 9, 2023

Multiple Myeloma Trial in Charlotte (Elotuzumab)

Active, not recruiting
Has Results
  • Multiple Myeloma
  • Charlotte, North Carolina
    Levine Cancer Institute
Jan 24, 2023

Kyprolis® in Combination With Revlimid® and Dexamethasone or

Recruiting
  • Multiple Myeloma in Relapse
  • Carfilzomib
  • Frankfurt, Germany
    Centrum für Hämatologie und Onkologie Bethanien
Jun 2, 2022

Relapsed Multiple Myeloma in France in Context of Carfilzomib

Completed
  • Relapsed Multiple Myeloma
    • Le Mans, France
      Centre Hospitalier Du Mans
    Mar 8, 2022

    Waldenstrom Macroglobulinemia Trial in Hackensack (Carfilzomib, Rituximab, Dexamethasone)

    Completed
    Has Results
    • Waldenstrom Macroglobulinemia
    • Carfilzomib
    • +2 more
    • Hackensack, New Jersey
      John Theurer Cancer Center at Hackensack University Medical Cent
    Mar 18, 2022

    Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Portland (Carfilzomib, Isatuximab, Pomalidomide)

    Recruiting
    • Recurrent Plasma Cell Myeloma
    • Refractory Plasma Cell Myeloma
    • Carfilzomib
    • +2 more
    • Portland, Oregon
      OHSU Knight Cancer Institute
    Jun 14, 2022

    Multiple Myeloma Trial (Carfilzomib delivered in OH only, Carfilzomib delivered in OH and HaH combined)

    Not yet recruiting
    • Multiple Myeloma
    • Carfilzomib delivered in OH only
    • Carfilzomib delivered in OH and HaH combined
    • (no location specified)
    Dec 21, 2021

    Multiple Myeloma Trial in New York (carfilzomib, Dexamethasone, Clarithromycin)

    Active, not recruiting
    Has Results
    • Multiple Myeloma
    • carfilzomib
    • +3 more
    • New York, New York
      Weill Cornell Medical College
    Apr 10, 2022

    Multiple Myeloma Trial in Oslo, Trondheim (Hydroxychloroquine, Carfilzomib Injection, Dexamethasone)

    Completed
    • Multiple Myeloma
    • Oslo, Norway
    • +1 more
    Mar 16, 2022

    Multiple Myeloma Trial (Elranatamab, Elotuzumab, Pomalidomide)

    Not yet recruiting
    • Multiple Myeloma
    • (no location specified)
    Nov 28, 2023

    Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma Trial in Canada, United States (drug, procedure,

    Active, not recruiting
    Has Results
    • Stage I Multiple Myeloma
    • +2 more
    • Chicago, Illinois
    • +4 more
    Sep 3, 2022

    Multiple Myeloma Trial in Seoul (Lenalidomide maintenance)

    Recruiting
    • Multiple Myeloma
    • Lenalidomide maintenance
    • Seoul, Korea, Republic of
      Samsung Medical Center
    Aug 10, 2022

    Multiple Myeloma Trial in Torino (Carfilzomib, Cyclophosphamide, Dexamethasone)

    Active, not recruiting
    • Multiple Myeloma
    • Carfilzomib
    • +2 more
    • Torino, Italy
      Fondazione EMN Italy Onlus
    Mar 24, 2022